Skip to content
2000
Volume 15, Issue 14
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Diseases started even before the existence of human beings. Therefore, when the civilization began, the biggest threats for human were diseases. Man has made several sincere attempts for the search of new drugs in order to cure and control different diseases. Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that accounts for about 85-95% of all diagnosed cases of diabetes. It is characterized by abnormalities in glucose homeostasis in many organs, and is associated with considerable morbidity and mortality. Extensive research has been carried out using rational drug design to identify and optimize new leads for molecular targets of T2DM, which include Heterocyclic compounds, metal complexes, H3 receptor antagonists, glucagon receptor antagonists and human incretin-degrading enzyme dipeptidyl peptidase IV inhibitors.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557515666150722112942
2015-12-01
2025-09-28
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557515666150722112942
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test